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(OS) were estimated using Kaplan-Meier methods, and time-
to-relapse and non-relapse mortality (NRM) were estimated
using cumulative incidence functions. Cox regression was
used to further investigate the association between chime-
rism and the risk of NRM adjusted for key covariates.
Results: Of 161 patients identiﬁed, 96 were disease free and
had PB TC chimerism at 3 month Table 1 lists transplant
characteristics and outcomes. PB TC MC was observed in 64
(66%) at 3 month There was no difference in chimerism
based on disease, stem cell source, HLA-match, donor-
recipient gender pairing, or conditioning regimen. Relapse
and DFS were not different between the MC and full donor
chimerism groups. However, NRM was signiﬁcantly higher
(P-value 0.001) and OS was signiﬁcantly lower (P-value 0.01)
in the full donor chimerism group at 2 years. Using Cox
regression, the association between chimerism and NRM
remained after adjusting for DLI, disease, conditioning
regimen and donor-recipient sex (P value 0.03). Analysis of 6
month PB TC chimerism also showed patients withMC in the
PB at 6 months had less NRM and improved OS than patients
with full donor chimerism.
Conclusions: In this analysis of PB TC chimerism following
TCD transplant, both NRM and OSwere signiﬁcantly better in
patients with MC. These data suggest that DLI for the
conversion of MC to full chimerism may be unnecessary.385
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Intraduodenal haematoma (IDH) has been noted usually
after blunt abdominal trauma. It has been recognized as
a complication of endoscopic biopsy and the risk is high in
patients with bleeding disorders. History of bone marrow
transplantation seems tobe relevant risk factor. The incidence
is estimated to be 1/1250 upper gastrointestinal endoscopies.
The diagnosis is likely if symptoms of acute abdominal pain
and vomiting occur within 48 hours after duodenal biopsy.
The symptoms are usually caused by duodenal obstruction.
Pancreatitis may develop. Conservative management is the
preferred approach if perforation is excluded. Complete
resolution generally occurs within 2-3 weeks.
A-18-year old girl with acute lymphoblastic leukemia
underwent allogeneic peripheral blood stem cell trans-
plantation. Diarrhea developed on the third month and
gastrointestinal endoscopic biopsies were performed for
GVHD evaluation. The mucosa of stomach was reddish and
edematous but other parts looked normal. Three hours later
the patient had severe vomiting, intense abdominal tender-
ness and massive haematemesis which required red cell
transfusions. A second look revealed active hemorrhage from
biopsy side at the cardioesophageal junction. Epinephrine
injectionwas performed and the clinical status was related to
Mallory-Weiss tear due to severe vomiting. However her
complaints persisted despite full supportive treatment.Abdominal CT scan revealed a 9 cm mass with diameter of 5
cmwithin the second and third duodenal portions consistent
with an intramural haematoma. There was also hemoper-
itoneum. Since perforation was excluded conservative
management was initiated including bowel rest, parenteral
nutrition and nasogastric decompression. On day 14 serum
bilirubin levels reached 7.5 mg/dl with GGT:393 U/L, ALP:329
U/L values. MRI revealed 8x4 cm haematoma compressing
the ampulla of Vater. She improved in the following days.
Haematoma regressed to 3 cm on the 4th week and the
patient was discharged.
In our patient blood counts and coagulation tests were
within normal limits at the time of endoscopic intervention.
Biopsies were consistent with GVHD and the mucosal
damage caused by this condition may have been contributed
to duodenal vulnerability. Depending on other reported
cases with bone marrow transplantation we can conclude
that endoscopic interventions should be carefully employed
in this subgroup of patients.386
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BKVN is reported in 8% of renal transplant (RT) patients
(pts) and leads to renal failure/graft loss if untreated. In HSCT
BKV is mainly associated with hemorrhagic cystitis (HC),
with few BKVN cases reported to-date. In RT, treatment (tx)
is primarily immunosuppression reduction, not feasible in
HSCT due to the risk of graft versus host disease (GvHD). IV
cidofovir (CDV) is used as adjunctive tx, but is associated
with signiﬁcant nephrotoxicity. At MSKCC, we have had 5
HSCT pts with tissue-proven BKVN in past 6 yrs. Diagnosis
(dx) was by biopsy in 2, autopsy in 2 and nephrectomy in 1.
Three pts received T‑cell depleted (TCD) grafts, 3 had GvHD
and 3 CMV disease. Three had severe HC with clot obstruc-
tion. Two pts developed end-stage renal disease (ESRD)
requiring hemodialysis (HD) despite tx with CDV. ESRD
preceded the BKVN dx. We present 1 HSCT pt treated for
BKVNwith CMX001 in an open-label, expanded access study
(CMX001-350; ClinicalTrials.gov ID: NCT01143181). CMX001
is an orally bioavailable, broad spectrum, lipid acyclic
nucleoside phosphonate converted intracellularly into the
active antiviral CDV. The pt (58 YO white male) with history
of chronic lymphocytic leukemia/small lymphocytic
lymphoma (SLL) transformed to a diffuse, large B-cell
lymphoma received a TCD graft from a matched, unrelated
donor. He had SLL relapse +6 mos post-HSCT (tx with
chemotherapy, donor lymphocyte infusion and lenalido-
mide), complicated by grade IV steroid-refractory acute
Table
Parameter BL Change from BL at:
Wk2 Wk3 Wk4 Wk5 Wk7 Wk9 Wk11 Wk13 Mo4 Mo5 Mo6
BK viremia* (log10 c/mL) 6.2 -0.6 -1.4 -1.8 -2.1 -2.4 -2.7 -3.0 -3.0 -3.9 -3.9 -3.3
BK viruria* (log10 c/mL) 8.7 ND ND -0.7 -1.0 -1.1 -1.5 ND -1.9 -2.1 ND ND
Cr (mg/dL) 2.6 +0.5 +0.3 +0.6 +0.5 +1.0 +0.8 +1.1 +1.2 +0.9 +1.0 +1.3
BUN (mg/dL) 39 -2 -3 0 -2 0 -4 -4 -2 +2 -7 -9
GFR (mL/min/1.73m2) 27.1 -5.0 -3.2 -5.8 -5.0 -8.5 -7.2 -9.1 -9.6 -7.9 -8.5 -10.2
ND indicates not determined
* Viracor BKV qPCR assays in plasma (LLOD, 2 log10 c/mL) or urine (LLOD ¼ 2.7 log10 c/mL)
Figure 1.
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[MMF]). He has remained on sirolimus and MMF. At +16 mos
serum creatinine (Cr) was increasing, BKVN was diagnosed
by biopsy and he was enrolled in CMX001-350.
Methods: CMX001 was given orally at 100 mg twice-weekly
for 6 mos (max tx duration under CMX001-350). Pt was
assessed weekly (Wks 2-5), biweekly (Wks 7-13), and
monthly (Mos 4-6).
Results: Baseline (BL) and changes from BL in BK viremia/
viruria, Cr, BUN and estimated glomerular ﬁltration rate
(GFR, MDRD4) are shown below. No drug-related adverse
events (AEs) or serious AEs were reported. The pt continues
on CMX001 under separate EIND provisions and has stable
renal function and no HD.
Conclusions: BKVN may be underdiagnosed in HSCT. In 1 pt
treated with CMX001, the drug was well tolerated and
controlled the BK viremia. After 6 mos therapy, he has stable
renal functionwithout HD. Our data supports a potential role
for CMX001 in the tx of BKVN.
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Dose intensity is important for disease control in alloge-
neic stem cell transplant (AlloSCT). There is no prospective
data to determine the ideal dose for intravenous busulfan to
be used in reduced intensity AlloSCT. We conducted a phase
I/II controlled randomized study to determine the optimal
dosing schedule of intravenous busulfan. Patients with
advanced hematologic malignancies, 75 years with HLA-
compatible donor were eligible. In the phase 1 portion, seven
dose levels were explored. All patients received ﬂudarabine
at 30mg/m2/d for 4 days. Dose level 5 (11.2mg/kg) was
chosen to be tested for phase II cohort. Eighty patients with
a median age of 56 years were enrolled with 40% having
relapsed/refractory disease. Engraftment occurred in 91%
and complete response was documented in 79% patients
after undergoing transplant. At a median follow up of 91
months, no signiﬁcant difference was seen in terms of non-
relapse mortality of 34% for dose level 5 (11.2mg/kg) vs. 23%
for all other dose levels (P ¼ .4). Signiﬁcant improvement in
cumulative incidence of relapse of 43% vs. 68% (P ¼ .02);
relapse-free-survival of 25% vs. 9% (P ¼ .017) and overall-survival of 27% vs. 9% (P ¼ .037) (Figure 1) was demonstrated
with the dose intensiﬁcation of busulfan. We conclude that
optimizing intravenous busulfan dose intensity in the
preparative regimen leads to improvement in PFS and OS of
patients with advanced hematologic malignancies and may
overcome disease associated poor prognostic factors.388
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Background: Several methods are employed to predict the
outcome of patients undergoing allogeneic hematopoietic
cell transplantation (HCT), including patient characteristics
(e.g., age, performance status, concurrent comorbidities),
diagnosis, and disease status. Armand, et al. (Blood
2012;120:905-913) validated a disease risk index using
diagnosis, cytogenetics, and disease status, which predicted
for overall and progression-free survival. To test this disease
risk index in our patient population, we applied it to patients
receiving ﬂudarabine and pharmacokinetically dose-tar-
geted intravenous busulfan myeloablative conditioning fol-
lowed by allogeneic peripheral blood HCT.
Methods:We analyzed a cohort of 322 patients transplanted
between 2004 and 2009 and assigned them to disease (low,
intermediate, and high) and stage (low and high) risk groups
